Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 4, 2011, Pages 612-619

  Jung, K H ^a   Chu, K ^a   Lee, S T ^a   Yoon, H J ^a   Chang, J Y ^a   Nam, W S ^a,b   Yoon, S H ^a,b   Cho, J Y ^a,b   Yu, K S ^a,b   Jang, I J ^a,b   Kim, M ^a   Lee, S K ^a   Roh, J K ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; ASPIRIN; CACO-2 CELLS; CELL SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TICLOPIDINE;

EID: 80052969127     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.163     Document Type: Article

References (37)

1. van, W.I. et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 365, 2098-2104 (2005).
2. Usman, M.H. et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am. J. Cardiol. 103, 1107-1112 (2009).
3. Bhatt, D.L. et al.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
4. Rothwell, P.M. Lessons from MATC H for future randomised trials in secondary prevention of stroke. Lancet 364, 305-307 (2004). (Pubitemid 38969990)
5. Squizzato, A., Keller, T., Romualdi, E. & Middeldorp, S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst. Rev. CD005158 (2011).
6. Peace, A.J., Tedesco, A.F., Foley, D.P., Dicker, P., Berndt, M.C. & Kenny, D. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J. Thromb. Haemost. 6, 2027-2034 (2008).
7. Mega, J.L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
8. Simon, T. et al.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
9. C ollet, J.P. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317 (2009).
10. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
11. Sharis, P.J., Cannon, C.P. & Loscalzo, J. The antiplatelet effects of ticlopidine and clopidogrel. Ann. Intern. Med. 129, 394-405 (1998). (Pubitemid 28402795)
12. Hulot, J.S. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244-2247 (2006).
13. Fontana, P., Senouf, D. & Mach, F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb. Res. 121, 463-468 (2008). (Pubitemid 351174278)
14. O'Donoghue, M.L. et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374, 989-997 (2009).
15. Par? G. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363, 1704-1714 (2010).
16. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
17. T aubert, D. et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. 92, 311-316 (2004).
18. Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A. & Borst, P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96, 1698-1705 (1995).
19. Mizuno, N., Niwa, T., Yotsumoto, Y. & Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 55, 425-461 (2003). (Pubitemid 37013212)
20. T aubert, D. et al. Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther. 80, 486-501 (2006).
21. Jett L., Beaulieu, E., Leclerc, J.M. & Biveau, R. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am. J. Physiol. 270, F756-F765 (1996).
22. Verschraagen, M., Koks, C.H., Schellens, J.H. & Beijnen, J.H. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res. 40, 301-306 (1999). (Pubitemid 29472055)
23. Rotem, R., Tzivony, Y. & Flescher, E. Contrasting effects of aspirin on prostate cancer cells: suppression of proliferation and induction of drug resistance. Prostate 42, 172-180 (2000). (Pubitemid 30080415)
24. Flescher, E., Rotem, R., Kwon, P., Azare, J., Jaspers, I. & Cohen, D. Aspirin enhances multidrug resistance gene 1 expression in human Molt-4 T lymphoma cells. Anticancer Res. 20, 4441-4444 (2000). (Pubitemid 32141800)
25. T aipalensuu, J. et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299, 164-170 (2001). (Pubitemid 32905131)
26. T oyobuku, H., Tamai, I., Ueno, K. & Tsuji, A. Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. J. Pharm. Sci. 92, 2249-2259 (2003). (Pubitemid 37356698)
27. Jin, S. & Scotto, K.W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell. Biol. 18, 4377-4384 (1998). (Pubitemid 28287960)
28. Geick, A., Eichelbaum, M. & Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276, 14581-14587 (2001).
29. T rautwein, C., Caelles, C., van der Geer, P., Hunter, T., Karin, M. & Chojkier, M. Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain. Nature 364, 544-547 (1993). (Pubitemid 23273102)
30. C ombates, N.J., Rzepka, R.W., Chen, Y.N. & Cohen, D. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J. Biol. Chem. 269, 29715-29719 (1994). (Pubitemid 24365130)
31. Meade, E.A., Smith, W.L. & DeWitt, D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268, 6610-6614 (1993). (Pubitemid 23099364)
32. T sujii, M. & DuBois, R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493-501 (1995).
33. Shiff, S.J., Qiao, L., Tsai, L.L. & Rigas, B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96, 491-503 (1995).
34. Shiff, S.J., Koutsos, M.I., Qiao, L. & Rigas, B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp. Cell Res. 222, 179-188 (1996). (Pubitemid 26043724)
35. von Beckerath, N. et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur. Heart J. 28, 1814-1819 (2007). (Pubitemid 47236637)
36. Angiolillo, D.J. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115, 708-716 (2007). (Pubitemid 46294761)
37. Thomas, H. & Coley, H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165 (2003). (Pubitemid 36437822)